TRAVERE THERAPEUTICS

Travere Therapeutics to Present at Upcoming Investor Conferences

01 Jun 2023 15:30:00 By Nasdaq GlobeNewswire

Travere Therapeutics Announces Positive Topline Results from Cohort 6 in the Phase 1/2 COMPOSE Study of Pegtibatinase in Classical Homocystinuria

31 May 2023 06:00:00 By Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11 May 2023 16:00:00 By Nasdaq GlobeNewswire

Travere Therapeutics Reports First Quarter 2023 Financial Results

04 May 2023 15:01:00 By Nasdaq GlobeNewswire

Travere Therapeutics Announces Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis

01 May 2023 15:05:36 By Nasdaq GlobeNewswire

Travere Therapeutics to Report First Quarter 2023 Financial Results

26 Apr 2023 15:30:00 By Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

13 Apr 2023 16:00:00 By Nasdaq GlobeNewswire

Travere Therapeutics Announces Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy Published in The Lancet and Presented at World Congress of Nephrology 2023

01 Apr 2023 03:30:00 By Nasdaq GlobeNewswire

Travere Therapeutics to Present at Upcoming Investor Conferences

28 Mar 2023 15:30:00 By Nasdaq GlobeNewswire

Travere Therapeutics Announces Late-Breaker Presentations of the Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy at the ISN World Congress of Nephrology and NKF Spring Clinical Meetings 2023

23 Mar 2023 15:30:00 By Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

14 Mar 2023 16:00:00 By Nasdaq GlobeNewswire

Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders 44th Annual Meeting and the American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting 2023

14 Mar 2023 15:30:00 By Nasdaq GlobeNewswire

Travere Therapeutics Announces Completion of Public Offering of Common Stock and Pre-Funded Warrants and Exercise in Full of Underwriters’ Option to Purchase Additional Shares

03 Mar 2023 15:05:00 By Nasdaq GlobeNewswire

Travere Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

28 Feb 2023 21:36:49 By Nasdaq GlobeNewswire

Travere Therapeutics Announces Proposed Public Offering of Common Stock

27 Feb 2023 15:01:00 By Nasdaq GlobeNewswire

Travere Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

23 Feb 2023 15:01:00 By Nasdaq GlobeNewswire

Travere Therapeutics Announces FDA Accelerated Approval of FILSPARITM (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy

17 Feb 2023 15:04:25 By Nasdaq GlobeNewswire

Travere Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results

16 Feb 2023 15:30:00 By Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

13 Feb 2023 16:00:00 By Nasdaq GlobeNewswire

Travere Therapeutics to Present at Upcoming Investor Conferences

08 Feb 2023 15:30:00 By Nasdaq GlobeNewswire